author-photo

J. A. Sosman

Vanderbilt University

39

Papers

4353

Citations

Citation Trend

Filter By

Papers (31) Sort By

Journal Conference Others

Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (10)
A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI)

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (13)
Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (45)
Impact of key prognostic factors on long-term overall survival in BRAFV600-mutated metastatic melanoma patients treated with vemurafenib in the BRIM-3 study

2016 Melanoma Research
Show All
- Source
- Cite
- Save
Citations (1)
A phase I dose escalation study of OSI-906 in patients with advanced solid tumours

2015 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
1086OPHASE IB/II STUDY OF LEE011 (CDK4/6 INHIBITOR) AND LGX818 (BRAF INHIBITOR) IN BRAF-MUTANT MELANOMA

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (16)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

2014 Nature
Show All
- Source
- Cite
- Save
Citations (3218)
1088PDLONG-TERM SURVIVAL OF IPILIMUMAB-NAïVE PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) TREATED WITH NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN A PHASE 1 TRIAL

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (8)
809OIMMUNE CORRELATES AND LONG TERM FOLLOW UP OF A PHASE IA STUDY OF MPDL3280A, AN ENGINEERED PD-L1 ANTIBODY, IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (26)
First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma.

2011 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)